Ovarian01 Phase 3 Trial of ENHERTU® Initiated as First-Line Maintenance Therapy in Patients with HER2 Expressing Advanced ...

Adding a targeted agent to chemotherapy failed to improve survival as initial therapy for metastatic urothelial carcinoma, a randomized trial showed. Median overall survival (OS) was about 14 months ...

April 30, 2012 (Miami, Florida) — The use of bevacizumab to treat recurrent glioblastoma multiforme (GBM) may raise the risk for secondary gliosarcoma (GS). Bevacizumab (Avastin, Genentech), an ...

Bevacizumab (Avastin, Genentech, Inc) is not cost-effective as a first-line treatment for newly diagnosed glioblastoma owing to its limited impact on patient outcomes, the results of a Canadian ...

CREATE Medicines Inc., a clinical-stage biotechnology company pioneering in vivo multi-immune programming, today announced ...

CHICAGO – Interim results from the phase-3 ICON7 trial showed that some women with stage III/stage IV ovarian cancer who underwent surgery were more likely to survive if they were assigned to ...

Use of anti-VEGF therapies varies by both U.S. Census region and patient population, according to research presented at the ...

Immunotherapy of Relapsed and Refractory Solid Tumors With Ex Vivo Expanded Multi-Tumor Associated Antigen Specific Cytotoxic T Lymphocytes: A Phase I Study The combination of maintenance bevacizumab ...

Thirty eyes of 30 diabetic patients were treated with 2.5 mg of intravitreal bevacizumab injection as the primary therapy for diabetic macular oedema. The main outcome measures included best-corrected ...

Alymsys from Amneal Pharmaceuticals and mAbxience is the third biosimilar referencing Avastin approved in the United States and the second of 3 biosimilar approvals Amneal expects in 2022. The FDA has ...